• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

AARP report details increase in brand name drug prices

December 14, 2016 By Sarah Faulkner

AARP report details increase in brand name drug pricesThe AARP Public Policy Institute released a report today showing that 2015 was the 4th straight year of double-digit average annual increases for widely used brand name drugs. The nonprofit organization also concluded that prices for brand name drugs increased almost 130 times faster than the 0.1% general inflation rate in 2015.

The report, which considered retail prices of 268 brand name prescription drugs used by older Americans between 2006 and 2015, found that the average cost for a single brand name drug for a chronic condition is nearly $6,000. Since the average older American takes 4.5 prescription drugs each month, the AARP’s report calculated the average annual cost of treatment is $26,000. The report’s authors pointed out that this is almost $2,000 more than the median income for Medicare beneficiaries.

Out of the 6 drugs with the highest price increases over the study period, 5 of them were marketed by Valeant Pharmaceuticals (NYSE:VRX). Valeant’s anti-anxiety drug, Ativan, increased in price by 2,873% between 2006 and last year. Most of the brand name prescription drugs that the report considered saw retail price increases in the past decade.

“This new report once again highlights the high and unrelenting price increases that are shockingly common in the pharmaceutical market,” AARP chief public policy officer Debra Whitman said in prepared remarks. “What’s particularly remarkable is that these incredibly high price increases are still occurring in the face of the intense public and congressional criticism of prescription drug pricing practices.”

“Prescription drug therapy is not affordable when its cost exceeds the patient’s entire income,” co-author Leigh Purvis added. “Even if patients are fortunate enough to have good health care coverage, high prescription drug costs translate into higher out-of-pocket costs—especially for those who pay a percentage of drug costs rather than a fixed copayment—as well as higher premiums, deductibles, and other forms of cost-sharing.”

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Valeant Pharmaceuticals

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS